A Department of Defense (DOD) Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans. The intranasal racemic ketamine was developed by biotech company Seelos Therapeutics (NASDAQ: SEEL)
See Also: Why Seelos Therapeutics Shares Are Diving Today
The Study
The new Phase 2 study will use an adaptive platform trial design involving a 30-day screening period, a 12-week treatment period, and a four-week follow-up to assess safety, tolerability and efficacy of multiple doses of SLS-002 paired with therapy.
Project managers will “guide the development of medical products for th. Army Medical Department and ...